Bristol-Myers Squibb (BMY) Revenue — Quarter Ended Jun 30, 2024
Bristol-Myers Squibb reported higher total revenues for the quarter. The increase reflects growth compared with both the prior quarter and the same quarter last year.
Key takeaway
Quarter ended Jun 30, 2024 · FY2024 Q2
Bristol-Myers Squibb reported higher total revenues for the quarter. The increase reflects growth compared with both the prior quarter and the same quarter last year.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$12.2B
Revenue reported for this quarter.
Quarter-over-quarter
+2.8%
Change from the immediately preceding quarter.
Year-over-year
+8.7%
Change from the comparable year-ago quarter.
Trailing four quarters
$46.5B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2023 | $11B | -2.2% |
| Dec 31, 2023 | $11.5B | +0.6% |
| Mar 31, 2024 | $11.9B | +4.7% |
| Jun 30, 2024 | $12.2B | +8.7% |
Revenue performance
Revenues rose sequentially from the immediately preceding quarter and also advanced versus the same quarter one year earlier.
Quarterly comparison
Compared with the prior quarter, total revenues were higher. Compared with the same quarter a year ago, total revenues were also higher.
What to watch
The company’s net debt position increased significantly during the first half of the year, primarily driven by payments for acquisitions and collaborations.